Angel Biotechnology

Angel to Further Produce ReN0

RNS Number : 5399Y
Angel Biotechnology Holdings Plc
23 December 2010



23 December 2010



("Angel" or "the Company")


Angel to Further Produce ReN001 Stem Cells Batches for the PISCES Phase I Clinical Trial in Stroke Patients

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer is preparing to produce the stem cell batches required to dose the next cohort of patients in the PISCES clinical trial.  This follows the announcement from ReNeuron on the news of their positive independent safety review of progress of the first patient treated in the PISCES clinical trial of their ReN001 stem cell therapy for stroke.  The clinical trial will now progress to treatment of the remainder of the first patient cohort with Angel continuing to provide the materials for use in this trial.



Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: "Angel is very pleased to hear the news that ReNeuron have been given the green light to continue with the PISCES clinical trial.  As ReNeuron's manufacturing partner Angel is a critical component of this ground breaking clinical trial and we look forward to manufacturing ReN001 cells for the next cohorts.  Provision of the highest quality manufacturing and regulatory support for such advanced biological therapies is Angel's core competence and this milestone confirms Angel's ability to deliver materials on time and to the highest standards thus successfully facilitating our client's clinical trials."


For further information, please call:

Angel Biotechnology Holdings plc

Tel: +44 (0) 131 445 6077

Gordon Sherriff - COO

Tel: +44 (0) 7951 057016

Grant Thornton Corporate Finance

Tel: +44 (0) 20 7383 5100 

Philip Secrett, Colin Aaronson

Matrix Corporate Capital LLP

Tel +44 (0) 20 3206 7000

Steve Cox/Stephen Waterman

The Communications Portfolio Ltd

Tel +44 (0) 20 7536 2028

Ariane Comstive, Media enquiries

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide.  Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.  Angel specializes in the provision of advanced biologics including  autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage.  Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005.

More information at

About ReNeuron Group plc


ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.  


ReNeuron has used its proprietary, patented cell expansion technology to generate genetically stable neural stem cell lines.  This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch.  Cell growth can therefore be completely arrested prior to in vivo implantation.  ReNeuron's clinically-tested cell encapsulation technology provides a method of protecting cells when transplanted, as well as reducing or eliminating the host immune response that might otherwise occur post-transplantation.


ReNeuron has filed for approval to commence initial clinical studies with its lead ReN001 stem cell therapy for chronic stroke disability.  There are an estimated 50 millionstroke survivors worldwide, approximately one half of which are left with permanent disabilities.  The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.  In addition to its stroke programme, ReNeuron is developing stem cell therapies for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of the retina.


ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas - its ReNcell®range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by Millipore Corporation.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at


This information is provided by RNS
The company news service from the London Stock Exchange